Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with ∼71 million chronically infected individuals worldwide. Treatment of patients with HCV-related liver disease has advanced considerably thanks to the development of new direct-acting antiviral drugs that are now administered as highly potent, safe, and well-tolerated combinations with a high barrier to resistance. International organizations, such as the European Association for the Study of the Liver, the American Association for the Study of Liver Diseases jointly with the Infectious Diseases Society of America, or the World Health Organization have published detailed treatment guidelines. With these therapies becoming more and more widely available, elimination of hepatitis C as a public health threat by 2030 can now be envisaged in several countries. In other regions, better screening, diagnosis, and linkage to care will be necessary to achieve this ambitious goal.

中文翻译：

---

无干扰素丙型肝炎病毒治疗

丙型肝炎病毒（HCV）感染是慢性肝病的主要原因，全世界约有7100万慢性感染者。得益于新的直接作用抗病毒药物的开发，丙型肝炎病毒相关的肝病患者的治疗已取得了显着进展，这些新药物现在以高效，安全和耐受性良好的组合以及对耐药性的高抵抗力给予治疗。国际组织，例如欧洲肝病研究协会，美国肝病研究协会以及美国传染病学会或世界卫生组织，已经发布了详细的治疗指南。随着这些疗法的日益普及，现在可以在几个国家中设想到2030年消除丙型肝炎这一对公共健康的威胁。